Capital Research reports 8.3% stake in Vertex

Vertex Pharmaceuticals Inc. ownership disclosure: Capital Research Global Investors reports beneficial ownership of 21,139,169 shares, representing 8.3% of the 254,034,190 shares believed outstanding as of the filing.

Rhea-AI Filing Summary

Vertex Pharmaceuticals Inc. ownership disclosure: Capital Research Global Investors reports beneficial ownership of 21,139,169 shares, representing 8.3% of the 254,034,190 shares believed outstanding as of the filing. The filer states sole voting power over 21,113,307 shares and sole dispositive power over 21,139,169 shares. The filing is signed by a Vice President and Senior Counsel of Capital Research and Management Company.

Insights

Institutional Ownership Analyst

Large passive stake reported by a major investment manager.

Capital Research Global Investors discloses beneficial ownership of 21,139,169 shares, equal to 8.3% of the shares the filing cites as outstanding. The position is reported through investment management affiliates under the CRGI name.

The filing lists specific voting and dispositive powers; subsequent filings may clarify whether this reflects passive investment or active engagement.

Governance Specialist

Voting and dispositive power nearly aligned with beneficial holdings.

The filing shows sole voting power of 21,113,307 shares and sole dispositive power of 21,139,169 shares, indicating direct control over most of the reported stake. Such disclosures are standard for institutional managers consolidating affiliate holdings.

Material effects on governance depend on future actions by the holder; the filing itself does not state any proposals or intentions.

Key Figures

Beneficial ownership: 21,139,169 shares Percent of class: 8.3% Shares outstanding (referenced): 254,034,190 shares +3 more

6 metrics

Beneficial ownership 21,139,169 shares Amount beneficially owned reported on Schedule 13G/A

Percent of class 8.3% Percent of 254,034,190 shares believed outstanding

Shares outstanding (referenced) 254,034,190 shares Shares believed to be outstanding as cited in the filing

Sole voting power 21,113,307 shares Number of shares with sole power to vote reported by filer

Sole dispositive power 21,139,169 shares Number of shares with sole power to dispose reported by filer

Filing signature date 05/11/2026 Date on Schedule 13G/A signature block

Key Terms

Schedule 13G/A, Beneficial owner, Sole dispositive power

3 terms

Schedule 13G/A regulatory

"Capital Research Global Investors files a Schedule 13G/A amendment"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial owner financial

"CRGI is deemed to be the beneficial owner of 21,139,169 shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 21,139,169"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Capital Research Global Investors hold in VRTX?

Capital Research Global Investors beneficially owns 21,139,169 shares, representing 8.3% of the 254,034,190 shares cited as outstanding in the filing. The amount is reported on the Schedule 13G/A amendment.

How much voting power does CRGI report for Vertex (VRTX)?

CRGI reports sole voting power over 21,113,307 shares. The filing distinguishes sole voting power from dispositive power in the ownership tables.

Does this Schedule 13G/A indicate an activist intent by CRGI for VRTX?

The filing lists beneficial ownership and voting/dispositive powers but does not state any activism or proposal intent. The Schedule 13G/A format reports holdings; no engagement plans are disclosed in the excerpt.

Who signed the ownership filing for Capital Research Global Investors?

The Schedule 13G/A amendment is signed by Jae Won Chung, identified as Vice President and Senior Counsel II of Capital Research and Management Company, dated 05/11/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 10:19 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Vertex Pharmaceuticals Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

92532F100

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92532F100

1

Names of Reporting Persons

Capital Research Global Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 21,113,307.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 21,139,169.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

21,139,169.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Vertex Pharmaceuticals Inc.
(b)	Address of issuer's principal executive offices: 50 Northern Avenue, Boston, MA 02210, United States of America
Item 2.
(a)	Name of person filing: Capital Research Global Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 92532F100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 21,139,169 ** **Capital Research Global Investors ("CRGI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CRGI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital Research Global Investors." CRGI is deemed to be the beneficial owner of 21,139,169 shares or 8.3% of the 254,034,190 shares believed to be outstanding.
(b)	Percent of class: 8.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 21,113,307
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 21,139,169
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital Research Global Investors

Signature:	Jae Won Chung
Name/Title:	Vice President and Senior Counsel II, Capital Research and Management Company
Date:	05/11/2026